NCT05162040 is a clinical trial of Use of PedaleoVR in Ataxia, Motor, sponsored by Werium Assistive Solutions.

Who is sponsoring NCT05162040?

NCT05162040 is sponsored by Werium Assistive Solutions.

What drugs are being tested in NCT05162040?

Interventions in NCT05162040: Use of PedaleoVR.

What condition does NCT05162040 study?

NCT05162040 studies Ataxia, Motor, Hemiparesis.

Is NCT05162040 still recruiting?

NCT05162040 is currently completed. Last updated 17 December 2021.

Last reviewed 2021-12-17 · How we verify

NCT05162040

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

PedaleoVR: Credibility, Usability and Intrinsic Motivation Study

Completed Last updated 17 December 2021

What this trial tests

trial testing Use of PedaleoVR in Ataxia, Motor in 20 participants. Completed in 1 November 2021.

Timeline

1 October 2021

Primary endpoint
1 November 2021

1 November 2021

Quick facts

Lead sponsor	Werium Assistive Solutions
Status	Completed
Study type	OBSERVATIONAL
Enrollment	20
Start date	1 October 2021
Primary completion	1 November 2021
Estimated completion	1 November 2021
Sites	1 location across Spain

Drugs / interventions tested

Use of PedaleoVR

Conditions studied

Ataxia, Motor — all drugs for Ataxia, Motor →
Hemiparesis — all drugs for Hemiparesis →

Sponsor

Werium Assistive Solutions

Who can join

Adults 39 to 88, any sex, with Ataxia, Motor or Hemiparesis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The objective of this research is to combine the use of inertial systems with virtual reality in pedalling exercises in a pilot study with subjects with ataxia or hemiparesis. In particular, it is intended to evaluate the validity of the system as a physical training tool for pedalling exercises aimed at providing motivational visual stimuli and biofeedback based on pedalling cadence to improve the exercise experience and promote adherence to the subject's treatment. Primary objectives: * To study the estimation of pedalling cadence performed by the system/platform in subjects with hemiparesis or ataxia.. * To study the usability, credibility and intrinsic motivation characteristics of the platform

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

PedaleoVR: Usability study of a virtual reality application for cycling exercise in patients with lower limb disorders and elderly people.
Rojo A, Castrillo A, López C, Perea L, et al · · 2023 · cited 7× · PMID 36812248 · DOI 10.1371/journal.pone.0280743
Effects of a Virtual Reality Cycling Platform on Lower Limb Rehabilitation in Patients With Ataxia and Hemiparesis: Pilot Randomized Controlled Trial.
Rojo A, Castrillo Calvillo A, López C, Raya R, et al · · 2024 · cited 1× · PMID 38180843 · DOI 10.2196/39286

Verify or expand the search:

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05162040 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Werium Assistive Solutions
Last refreshed: 17 December 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05162040.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing